Perioperative venous thromboembolism prophylaxis: Difference between revisions

From IDWiki
(Imported from text file)
 
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
−
== Management ==
+
==Management==
   
−
* Non-orthopedic surgery
+
*Non-orthopedic surgery
−
** Can estimate risk using Caprini and Rogers scores
+
**Can estimate risk using Caprini and Rogers scores
−
** If very low risk, no prophylaxis
+
**If very low risk, no prophylaxis
−
** If low risk, intermittent pneumatic compression (IPC)
+
**If low risk, intermittent pneumatic compression (IPC)
−
** If moderate risk, IPC or UFH/LMWH
+
**If moderate risk, IPC or UFH/LMWH
−
** If high risk, UFH/LMWH
+
**If high risk, UFH/LMWH
−
** If cancer, continue prophylaxis for 4 weeks
+
**If cancer, continue prophylaxis for 4 weeks
−
** If significant bleeding risk, consider fondaparinux or aspirin
+
**If significant bleeding risk, consider fondaparinux or aspirin
−
* Orthopedic surgery
+
*Orthopedic surgery
−
** THA/TKA: LMWH for 14 to 35 days ± IPC
+
**Total hip or knee arthroplasty: LMWH for 14 to 35 days ± IPC
−
* Start prophylaxis 12 hours post-operatively unless significant bleeding concerns
+
*Start prophylaxis 12 hours post-operatively unless significant bleeding concerns
   
−
=== Medications ===
+
===Medications===
   
−
* LMWH: enoxaparin 40 mg daily or 30 mg BID, or dalteparin 5000 u daily
+
*In general, prefer [[low molecular weight heparin]] (LMWH): [[enoxaparin]] 40 mg daily or 30 mg BID, or [[dalteparin]] 5000 u daily
−
* UFH 5000 u BID
+
*If renal failure, can use [[unfractionated heparin]] (UFH) 5000 u BID
  +
*Alternatives include:
−
* Fondaparinux 2.5 mg daily
+
**[[Fondaparinux]] 2.5 mg daily
−
* DOACs
 
  +
**Direct oral anticoagulants
−
** Dabigatran 220 mg daily
 
−
** Rivaroxaban 10 mg daily
+
***[[Dabigatran]] 220 mg daily
  +
***[[Rivaroxaban]] 10 mg daily
−
** Apixaban 2.5 mg BID
+
***[[Apixaban]] 2.5 mg BID
−
* Wardarin
 
  +
**[[Warfarin]]
   
−
== Further Reading ==
+
==Further Reading==
   
  +
*Perioperative Management of Antithrombotic Therapy. ''CHEST''. 2012;141(2):e326S-e350S. doi: [https://doi.org/10.1378/chest.11-2298 10.1378/chest.11-2298]
−
* Chest Guidelines on Antithrombotic Therapy
 
   
 
[[Category:Perioperative medicine]]
 
[[Category:Perioperative medicine]]

Latest revision as of 07:27, 3 August 2020

Management

  • Non-orthopedic surgery
    • Can estimate risk using Caprini and Rogers scores
    • If very low risk, no prophylaxis
    • If low risk, intermittent pneumatic compression (IPC)
    • If moderate risk, IPC or UFH/LMWH
    • If high risk, UFH/LMWH
    • If cancer, continue prophylaxis for 4 weeks
    • If significant bleeding risk, consider fondaparinux or aspirin
  • Orthopedic surgery
    • Total hip or knee arthroplasty: LMWH for 14 to 35 days ± IPC
  • Start prophylaxis 12 hours post-operatively unless significant bleeding concerns

Medications

Further Reading

  • Perioperative Management of Antithrombotic Therapy. CHEST. 2012;141(2):e326S-e350S. doi: 10.1378/chest.11-2298